Meeting
2020 ASCO Virtual Scientific Program
Clinical outcome of patients experiencing central nervous system progression on first-line pertuzumab and trastuzumab for HER2-positive metastatic breast cancer in a real-life cohort.
Authors
Laetitia Collet
Centre Léon Bérard, Lyon, France
Laetitia Collet , Lauriane Eberst , Julien Fraisse , Marc Debled , Christelle Levy , Marie-ange Mouret-Reynier , Isabelle Desmoulins , Anthony Goncalves , Mario Campone , Jean-Marc Ferrero , Etienne Brain , Veronique Dieras , Thierry Petit , Gaetane Simon , Marianne Leheurteur , Florence Dalenc , Laurence Vanlemmens , Amelie Darlix , Monica Arnedos , Thomas Bachelot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2527)
DOI
10.1200/JCO.2020.38.15_suppl.2527
Abstract #
2527
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets).
First Author: Cristiano Ferrario
Poster
2022 ASCO Annual Meeting
Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.
First Author: Chris Labaki
Poster
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton